The demonstrated benefits of cannabidiol in the adjunctive treatment of schizophrenia

Health 30 December, 2017


Published the 28.12.2017 to 14h19


Keywords :


600 000 people with schizophrenia in France. Nearly half of them made a suicide attempt during the course of his life. After several years of treatment, it is possible for patients to achieve a remission phase. This affects about one-third of them. The medicine is always on the search for new drugs or ways to relieve the sick.
Researchers have shown that cannabidiol has anti-psychotic in a controlled study. This substance is a cannabinoid present in the cannabis. Scientists believe that it is an effective cure and safe. Their research was published in the American Journal of Psychiatry.

Treatment well borne by the patients

Tests have been conducted on animals and humans. At the end of six weeks of treatment, in eu study controlled double-blind, the group that received cannabidiol had fewer hallucinations and delusions than the placebo group. Because the symptoms of the disease are classified into two groups : positive symptoms, which are the paranoia, the megalomania, the delusions, the hallucinations. The negative symptoms are, on the contrary, a depletion of emotional and emotional isolation, loss of interest.
The group that received cannabidiol has also made the most progress in their cognitive performance. The treatment was well tolerated by the patients.

Cannabidiol, could help patients who do not tolerate the anti-psychotic ” classic “, to the side effects that are sometimes very binding.